0000000000445207

AUTHOR

Jodianne T. Wood

showing 2 related works from this author

A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents

2010

BACKGROUND AND PURPOSE Cannabinoid CB1 receptor antagonists reduce food intake and body weight, but clinical use in humans is limited by effects on the CNS. We have evaluated a novel cannabinoid antagonist (AM6545) designed to have limited CNS penetration, to see if it would inhibit food intake in rodents, without aversive effects. EXPERIMENTAL APPROACH Cannabinoid receptor binding studies, cAMP assays, brain penetration studies and gastrointestinal motility studies were carried out to assess the activity profile of AM6545. The potential for AM6545 to induce malaise in rats and the actions of AM6545 on food intake and body weight were also investigated. KEY RESULTS AM6545 binds to CB1 recep…

PharmacologyAM251medicine.medical_specialtyCannabinoid receptormedicine.medical_treatmentAntagonistPharmacologyBiologyEndocrinologyInternal medicinemedicineCannabinoid receptor bindingCannabinoid receptor type 2Cannabinoid receptor antagonistlipids (amino acids peptides and proteins)CannabinoidReceptormedicine.drugBritish Journal of Pharmacology
researchProduct

Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice

2012

Background and purpose Gastrointestinal (GI) motility is regulated in part by fatty acid ethanolamides (FAEs), including the endocannabinoid (EC) anandamide (AEA). The actions of FAEs are terminated by fatty acid amide hydrolase (FAAH). We investigated the actions of the novel FAAH inhibitor AM3506 on normal and enhanced GI motility. Experimental approach We examined the effect of AM3506 on electrically-evoked contractility in vitro and GI transit and colonic faecal output in vivo, in normal and FAAH-deficient mice treated with saline or LPS (100 µg·kg(-1), i.p.), in the presence and absence of cannabinoid (CB) receptor antagonists. mRNA expression was measured by quantitative real time-PCR…

Pharmacologymedicine.medical_specialtyCannabinoid receptormedicine.medical_treatmentdigestive oral and skin physiologyMotilityIleumAnandamideBiologyEndocannabinoid systemchemistry.chemical_compoundEndocrinologymedicine.anatomical_structurenervous systemchemistryFatty acid amide hydrolaseInternal medicinemedicinelipids (amino acids peptides and proteins)CannabinoidReceptorpsychological phenomena and processesBritish Journal of Pharmacology
researchProduct